文献速递艾滋病与性传播感染细菌感染、耐药与抗菌药物

多替拉韦重塑HIV-1储存库的遗传多样性

Dolutegravir reshapes the genetic diversity of HIV-1 reservoirs.
PubMed 文献 · J Antimicrob Chemother · 2018-01-01

所有个体均实现或维持病毒抑制;急性感染起始治疗者多样性低且稳定,其他个体第4周多样性骤降但至48周恢复,5例(25%)检出整合酶耐药相关替换但均未导致病毒学失败。

要点

  • 多替拉韦方案启动后HIV-1储存库遗传多样性先降后升,提示治疗下病毒可能继续复制。
  • 急性感染期起始治疗者储存库多样性低且稳定,其他个体第4周骤降后至48周恢复。
  • 5例(25%)检出整合酶50/124/230/263位耐药相关替换,但均未导致病毒学失败。

核心结论

  • 多替拉韦方案启动后HIV-1储存库遗传多样性被重塑。
  • 研究强烈提示尽管治疗成功,HIV-1可能继续复制。

研究设计与样本

  • 包括急性感染初治5例、慢性感染初治5例、换用多替拉韦方案且病毒学抑制5例、治疗失败5例。
  • 基线及第4、24、48周对PBMCs中HIV-1 DNA的整合酶和V3环区进行焦磷酸测序,以Shannon熵计算遗传多样性。

主要发现

  • 所有个体在研究期间实现或维持病毒抑制。
  • 急性感染期起始治疗者储存库准种遗传多样性低且稳定。
  • 其他个体治疗第4周遗传多样性骤降,但至48周尽管病毒学抑制,储存库遗传多样性恢复。
  • 5例(5/20,25%)检出携带整合酶50、124、230或263位多替拉韦耐药相关替换的病毒变异株,除基线治疗失败组外各组均有。
  • 上述替换均未导致病毒学失败。

临床怎么用

  • 多替拉韦方案治疗下应关注储存库遗传多样性动态及潜在病毒复制。
  • 检出整合酶耐药相关替换但病毒学抑制时,需结合临床判断,不必仅因替换改变方案。

局限性

  • 样本量小(20例),分组每组仅5例。
  • 仅分析PBMCs中HIV-1 DNA的整合酶和V3环区,未覆盖全基因组。
  • 随访48周,长期动态未知。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Better understanding of the dynamics of HIV reservoirs under ART is a critical step to achieve a functional HIV cure. Our objective was to assess the genetic diversity of archived HIV-1 DNA over 48 weeks in blood cells of individuals starting treatment with a dolutegravir-based regimen. METHODS: Eighty blood samples were prospectively and longitudinally collected from 20 individuals (NCT02557997) including: acutely (n = 5) and chronically (n = 5) infected treatment-naive individuals, as well as treatment-experienced individuals who switched to a dolutegravir-based regimen and were either virologically suppressed (n = 5) or had experienced treatment failure (n = 5). The integrase and V3 loop regions of HIV-1 DNA isolated from PBMCs were analysed by pyrosequencing at baseline and weeks 4, 24 and 48. HIV-1 genetic diversity was calculated using Shannon entropy. RESULTS: All individuals achieved or maintained viral suppression throughout the study. A low and stable genetic diversity of archived HIV quasispecies was observed in individuals starting treatment during acute infection. A dramatic reduction of the genetic diversity was observed at week 4 of treatment in the other individuals. In these patients and despite virological suppression, a recovery of the genetic diversity of the reservoirs was observed up to 48 weeks. Viral variants bearing dolutegravir resistance-associated substitutions at integrase position 50, 124, 230 or 263 were detected in five individuals (n = 5/20, 25%) from all groups except those who were ART-failing at baseline. None of these substitutions led to virological failure. CONCLUSIONS: These data demonstrate that the genetic diversity of the HIV-1 reservoir is reshaped following the initiation of a dolutegravir-based regimen and strongly suggest that HIV-1 can continue to replicate despite successful treatment.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Gantner P, Lee GQ, Rey D, et al. Dolutegravir reshapes the genetic diversity of HIV-1 reservoirs. J Antimicrob Chemother. 2018. PMID: 29244129. doi:10.1093/jac/dkx475

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。